167 related articles for article (PubMed ID: 32532543)
21. Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50-64 Years, and At-Risk Adults Aged 19-64 Years.
Choi MJ; Shin G; Kang D; Lim JO; Kim YK; Choi WS; Yun JW; Noh JY; Song JY; Kim WJ; Choi SE; Cheong HJ
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335077
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
24. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
[TBL] [Abstract][Full Text] [Related]
27. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
Nagy L; Heikkinen T; Sackeyfio A; Pitman R
Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
[TBL] [Abstract][Full Text] [Related]
28. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
29. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
Milne GJ; Halder N; Kelso JK; Barr IG; Moyes J; Kahn K; Twine R; Cohen C
Influenza Other Respir Viruses; 2016 Jul; 10(4):324-32. PubMed ID: 26663701
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.
Urueña A; Micone P; Magneres C; Mould-Quevedo J; Giglio N
Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33916048
[TBL] [Abstract][Full Text] [Related]
31. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
[TBL] [Abstract][Full Text] [Related]
32. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
[TBL] [Abstract][Full Text] [Related]
33. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
[TBL] [Abstract][Full Text] [Related]
34. Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination.
Tsuzuki S; Schwehm M; Eichner M
Vaccine; 2018 Jan; 36(5):624-630. PubMed ID: 29292176
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
[TBL] [Abstract][Full Text] [Related]
36. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
37. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
Van Bellinghen LA; Marijam A; Tannus Branco de Araujo G; Gomez J; Van Vlaenderen I
Braz J Infect Dis; 2018; 22(1):1-10. PubMed ID: 29352897
[TBL] [Abstract][Full Text] [Related]
38. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
[TBL] [Abstract][Full Text] [Related]
39. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico.
Ruiz-Palacios GM; Beigel JH; Guerrero ML; Bellier L; Tamayo R; Cervantes P; Alvarez FP; Galindo-Fraga A; Aguilar-Ituarte F; Lopez JG
Hum Vaccin Immunother; 2020 Apr; 16(4):827-835. PubMed ID: 31851570
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
